// App-Quantinova.ai

: Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c

Researchers

Presenter

  • CHRISTOPH WANNER

Principal Investigators

  • MARK E. COOPER

  • SILVIO INZUCCHI

  • BERNARD ZINMAN

  • UWE HEHNKE

  • MAXIMILIAN VON EYNATTEN

Medical Centers

  • N/A

Locations

  • Germany

  • Australia

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Cholesterol

  • Hemoglobin A1c

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved